Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MKKGY Merck KGaA	$26.08 -1.9%	$26.61	$24.32 ▼ $39.17	$16.85B	0.92	175,999 shs	50,651 shs
REGN Regeneron Pharmaceuticals	$545.00 -0.5%	$549.38	$476.49 ▼ $1,211.20	$59.10B	0.33	907,387 shs	456,413 shs
TAK Takeda Pharmaceutical	$15.55 +0.8%	$14.87	$12.80 ▼ $15.53	$48.81B	0.23	1.98 million shs	1.65 million shs
ZTS Zoetis	$159.19 +0.1%	$161.16	$139.70 ▼ $200.33	$70.87B	0.91	2.57 million shs	1.38 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MKKGY Merck KGaA	0.00%	-0.97%	-0.91%	+2.94%	-20.30%
REGN Regeneron Pharmaceuticals	0.00%	+4.61%	+12.82%	-4.96%	-46.78%
TAK Takeda Pharmaceutical	0.00%	+2.95%	+3.84%	+5.52%	+18.66%
ZTS Zoetis	0.00%	+1.94%	-5.58%	+4.90%	-9.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MKKGY Merck KGaA	3.6459 of 5 stars	0.0	5.0	2.5	0.0	1.7	0.0	3.1
REGN Regeneron Pharmaceuticals	4.9566 of 5 stars	4.4	5.0	1.7	2.3	3.3	1.7	1.9
TAK Takeda Pharmaceutical	1.2786 of 5 stars	0.0	3.0	2.5	0.0	2.7	0.0	0.6
ZTS Zoetis	4.8376 of 5 stars	3.5	5.0	4.2	0.4	3.1	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MKKGY Merck KGaA	3.00	Buy	N/A	N/A
REGN Regeneron Pharmaceuticals	2.80	Moderate Buy	$813.57	49.28% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A
ZTS Zoetis	3.00	Buy	$212.13	33.25% Upside

Current Analyst Ratings Breakdown

Latest MKKGY, ZTS, REGN, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00
6/5/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$633.00 ➝ $560.00
6/2/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$700.00 ➝ $650.00
6/2/2025	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$800.00 ➝ $600.00
6/2/2025	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$958.00 ➝ $755.00
5/30/2025	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/30/2025	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$662.00
5/30/2025	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$700.00 ➝ $580.00
5/27/2025	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Sector Perform	$943.00 ➝ $662.00

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MKKGY Merck KGaA	$22.57B	0.75	$8.15 per share	3.20	$50.22 per share	0.52
REGN Regeneron Pharmaceuticals	$14.20B	4.14	$45.49 per share	11.98	$268.50 per share	2.03
TAK Takeda Pharmaceutical	$30.09B	1.64	$3.23 per share	4.82	$14.39 per share	1.08
ZTS Zoetis	$9.26B	7.66	$7.07 per share	22.51	$10.57 per share	15.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MKKGY Merck KGaA	$3.00B	$2.11	12.35	12.72	1.94	13.23%	9.61%	5.59%	8/7/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.87	14.33	2.00	31.94%	15.27%	11.93%	8/1/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	70.69	9.42	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.57	28.58	23.58	2.64	27.12%	55.48%	19.14%	8/5/2025 (Estimated)

Latest MKKGY, ZTS, REGN, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.53	N/A	N/A	N/A	$3.30 billion	N/A
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	N/A	N/A	N/A	$7.96 billion	N/A
5/15/2025	Q1 2025	MKKGY Merck KGaA	$0.50	$0.59	+$0.09	$0.59	$5.32 billion	$5.89 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/6/2025	Q1 2025	ZTS Zoetis	$1.40	$1.48	+$0.08	$1.41	$2.20 billion	$2.22 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MKKGY Merck KGaA	$0.34	1.30%	N/A	16.11%	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.65%	N/A	8.96%	N/A
TAK Takeda Pharmaceutical	$0.55	3.54%	N/A	250.00%	N/A
ZTS Zoetis	$2.00	1.26%	N/A	35.91%	14 Years

Latest MKKGY, ZTS, REGN, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2025	ZTS Zoetis	quarterly	$0.50	1.2%	7/18/2025	7/18/2025	9/3/2025
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025
4/23/2025	MKKGY Merck KGaA		$0.3382	1.25%	4/29/2025	4/30/2025	5/7/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MKKGY Merck KGaA	0.23	1.31	0.83
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03
TAK Takeda Pharmaceutical	0.57	1.01	0.52
ZTS Zoetis	1.12	1.74	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MKKGY Merck KGaA	0.10%
REGN Regeneron Pharmaceuticals	83.31%
TAK Takeda Pharmaceutical	9.17%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
MKKGY Merck KGaA	N/A
REGN Regeneron Pharmaceuticals	7.02%
TAK Takeda Pharmaceutical	0.04%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MKKGY Merck KGaA	62,557	646.21 million	N/A	Not Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable
TAK Takeda Pharmaceutical	49,281	3.18 billion	3.18 billion	Optionable
ZTS Zoetis	13,800	445.21 million	444.41 million	Optionable

MKKGY, ZTS, REGN, and TAK Headlines

Recent News About These Companies

Zoetis Inc. (NYSE:ZTS) Stock Position Decreased by D.A. Davidson & CO.

1 hour ago | marketbeat.com

Novare Capital Management LLC Has $15.75 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

July 5 at 8:51 AM | marketbeat.com

Bank of New York Mellon Corp Decreases Stock Position in Zoetis Inc. (NYSE:ZTS)

July 5 at 8:26 AM | marketbeat.com

VELA Investment Management LLC Buys 3,823 Shares of Zoetis Inc. (NYSE:ZTS)

July 5 at 8:09 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Bought by Impax Asset Management Group plc

July 5 at 6:53 AM | marketbeat.com

IFM Investors Pty Ltd Buys 8,570 Shares of Zoetis Inc. (NYSE:ZTS)

July 5 at 6:28 AM | marketbeat.com

Calamos Advisors LLC Sells 87,156 Shares of Zoetis Inc. (NYSE:ZTS)

July 5 at 5:57 AM | marketbeat.com

Kintegral Advisory LLC Sells 9,036 Shares of Zoetis Inc. (NYSE:ZTS)

July 4 at 8:38 AM | marketbeat.com

Hartline Investment Corp Trims Position in Zoetis Inc. (NYSE:ZTS)

July 4 at 7:45 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Stock Holdings Increased by Fisher Funds Management LTD

July 4 at 7:28 AM | marketbeat.com

Calamos Wealth Management LLC Has $14.11 Million Stake in Zoetis Inc. (NYSE:ZTS)

July 4 at 7:18 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Position Increased by Aviance Capital Partners LLC

July 4 at 7:02 AM | marketbeat.com

Aurora Private Wealth Inc. Acquires New Position in Zoetis Inc. (NYSE:ZTS)

July 4 at 6:35 AM | marketbeat.com

Teacher Retirement System of Texas Decreases Position in Zoetis Inc. (NYSE:ZTS)

July 4 at 5:34 AM | marketbeat.com

Is Zoetis Gaining or Losing Market Support?

July 4 at 5:30 AM | benzinga.com

Zoetis Inc. (NYSE:ZTS) Shares Sold by First Horizon Advisors Inc.

July 4 at 5:26 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Palisade Capital Management LP

July 3 at 9:47 AM | marketbeat.com

Summit Place Financial Advisors LLC Buys 1,755 Shares of Zoetis Inc. (NYSE:ZTS)

July 3 at 9:02 AM | marketbeat.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Principal Financial Group Inc.

July 3 at 8:45 AM | marketbeat.com

ZTS | Zoetis Inc. Annual Income Statement | MarketWatch

July 3 at 8:27 AM | marketwatch.com

Zoetis Inc. (NYSE:ZTS) Shares Acquired by Tandem Investment Advisors Inc.

July 3 at 8:20 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MKKGY, ZTS, REGN, and TAK Company Descriptions

Merck KGaA OTCMKTS:MKKGY

$26.08 -0.51 (-1.90%)

As of 07/3/2025 12:57 PM Eastern

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Regeneron Pharmaceuticals NASDAQ:REGN

$545.00 -2.74 (-0.50%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$547.81 +2.81 (+0.52%)

As of 07/3/2025 04:57 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Takeda Pharmaceutical NYSE:TAK

$15.55 +0.13 (+0.84%)

Closing price 07/3/2025 03:32 PM Eastern

Extended Trading

$15.46 -0.09 (-0.57%)

As of 07/3/2025 05:00 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Zoetis NYSE:ZTS

$159.19 +0.11 (+0.07%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$159.19 0.00 (0.00%)

As of 07/3/2025 04:51 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time